序贯靶向α粒子治疗联合白细胞介素2免疫细胞因子改善CEA转基因小鼠CEA阳性乳腺与结肠肿瘤的疗效
在免疫健全的CEA转基因小鼠中,针对CEA阳性乳腺或结肠肿瘤,先给予低剂量(7.4 kBq)靶向α治疗(TAT)再于5或10天后给予4次免疫细胞因子方案,较单药治疗获得更优的肿瘤缩小和生存曲线;而免疫细胞因子后5天再给TAT的序贯方式在乳腺癌模型中与任一单药等效。
要点
- 低剂量TAT(7.4 kBq)后5或10天给予4次免疫细胞因子方案,在乳腺和结肠肿瘤模型中肿瘤缩小和生存曲线优于单药。
- 免疫细胞因子后5天再给TAT的序贯方式在乳腺癌模型中与任一单药等效。
- 序贯治疗组肿瘤浸润干扰素-γ阳性CD8阳性T细胞增加,且其与Foxp3阳性CD4阳性调节性T细胞比值升高。
核心结论
- 低剂量(7.4 kBq)TAT后5或10天给予4次免疫细胞因子方案,在乳腺和结肠肿瘤模型中较任一单药治疗获得更优的肿瘤缩小和生存曲线。
- 将治疗顺序颠倒为免疫细胞因子后5天再给TAT,在乳腺癌模型中与任一单药等效。
研究设计与样本
- 在免疫健全的CEA转基因小鼠中评估序贯靶向α治疗联合免疫细胞因子治疗CEA阳性乳腺或结肠肿瘤。
- 肿瘤靶向使用人源化抗CEA抗体M5A标记225Ac(半衰期10天,发射4个α粒子)及免疫细胞因子M5A-白细胞介素2。
主要发现
- 原位CEA阳性乳腺肿瘤中,单用TAT(3.7、7.4和11.1 kBq)呈剂量反应,最高剂量组肿瘤生长延迟30天,中位生存期从20天增至36天。
- 免疫细胞因子(每日4次)单药治疗肿瘤生长延迟20天,在免疫细胞因子开始后5天加用7.4 kBq TAT未改善该延迟。
- 7.4 kBq TAT后10天给予免疫细胞因子,肿瘤生长延迟38天,中位生存期增至45天;TAT后5天与10天给予免疫细胞因子的结果相似。
- 皮下植入CEA阳性MC38结肠肿瘤中,7.4 kBq TAT单药使中位生存期从29天增至42天;7.4 kBq TAT后10天加用免疫细胞因子使中位生存期增至57天。
- 免疫表型分析显示序贯治疗组肿瘤浸润干扰素-γ阳性CD8阳性T细胞增加,且其与Foxp3阳性CD4阳性调节性T细胞比值升高;免疫组化证实序贯治疗组肿瘤浸润CD8阳性T细胞增加。
关键数值与推荐
- TAT单药剂量为3.7、7.4和11.1 kBq,用于原位CEA阳性乳腺肿瘤的剂量反应评估。
- 免疫细胞因子给药方案为每日4次,作为单药治疗。
- 序贯方案为低剂量TAT(7.4 kBq)后5或10天给予4次免疫细胞因子方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted α-therapy (TAT) delivers high-linear-transfer-energy α-particles to tumors with the potential to generate tumor immune responses that may be augmented by antigen-targeted immunotherapy. Methods: This concept was evaluated in immunocompetent carcinoembryonic antigen (CEA) transgenic mice bearing CEA-positive mammary or colon tumors. Tumors were targeted with humanized anti-CEA antibody M5A labeled with 225Ac for its 10-d half-life and emission of 4 α-particles, as well as being targeted with the immunocytokine M5A-interleukin 2. Results: A dose response (3.7, 7.4, and 11.1 kBq) to TAT only, for orthotopic CEA-positive mammary tumors, was observed, with a tumor growth delay of 30 d and an increase in median survival from 20 to 36 d at the highest dose. Immunocytokine (4 times daily) monotherapy gave a tumor growth delay of 20 d that was not improved by addition of 7.4 kBq of TAT 5 d after the start of immunocytokine. However, TAT (7.4 kBq) followed by immunocytokine 10 d later led to a tumor growth delay of 38 d, with an increase in median survival to 45 d. Similar results were seen for TAT followed by immunocytokine at 5 versus 10 d. When a similar study was performed with subcutaneously implanted CEA-positive MC38 colon tumors, TAT (7.4 kBq) monotherapy gave an increase in median survival from 29 to 42 d. The addition of immunocytokine 10 d after 7.4 kBq of TAT increased median survival to 57 d. Immunophenotyping showed increased tumor-infiltrating interferon-γ-positive, CD8-positive T cells and an increased ratio of these cells to Foxp3-positive, CD4-positive regulatory T cells with sequential therapy. Immunohistochemistry confirmed there was an increase in tumor-infiltrating CD8-positive T cells in the sequential therapy group, strongly suggesting that immunocytokine augmented TAT can lead to an immune response that improves tumor therapy. Conclusion: Low-dose (7.4 kBq) TAT followed by a 4-dose immunocytokine regimen 5 or 10 d later gave superior tumor reductions and survival curves compared with either monotherapy in breast and colon cancer tumor models. Reversing the order of therapy to immunocytokine followed by TAT 5 d later was equivalent to either monotherapy in the breast cancer model.
引用
- Minnix M, Kujawski M, Poku E, et al. Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice. J Nucl Med. 2022. PMID: 35772959. doi:10.2967/jnumed.122.264126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。